VETO Vetoquinol SA

94.65USD86.30 EUR · EPA-0.46%Mkt Cap: 1.10B USDP/E: 15.86

Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Paci…

Institutional holders10 on file

Key Statistics

Company
Market Cap1.10B USD
Enterprise Value853.52M USD
Revenue (TTM)578.39M USD
Gross Profit430.85M USD
Net Income (TTM)62.91M USD
Revenue/Share50.14 USD
Last Price94.65 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINFR0004186856
Valuation
P/E (Trailing)15.86
P/E (Forward)14.78
PEG3.80
EV/EBITDA7.25
EV/Revenue1.48
P/S1.90
P/B1.64
EPS (TTM)5.97 USD
EPS (Forward)6.41 USD
52W Range
72.0680% of range100.36
52W High100.36 USD
52W Low72.06 USD
Profitability
Gross Margin74.73%
Oper. Margin15.98%
EBITDA Margin20.34%
Profit Margin10.91%
ROE9.70%
ROA7.51%
ROIC14.57%
ROCE12.79%
Growth
Revenue Growth0.60%
Earnings Growth23.50%
Cash Flow & Leverage
Operating CF79.05M USD
CapEx (TTM)22.73M USD
FCF Margin13.81%
FCF Yield7.26%
Net Debt-244.42M USD
Net Debt/EBITDA-2.08
Net Debt/FCF-3.06
Balance Sheet
Debt/Equity0.03
Current Ratio3.35
Quick Ratio2.36
Book Value/Sh57.56 USD
Cash/Share22.24 USD
Dividends
Fwd Div Rate1.02 USD
Trail. Div Rate1.02 USD
Div. Yield1.08%
5Y Avg Yield0.84%
Payout Ratio17.10%
Ex-Div DateJun 3, 2026
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)101.18 USD
Upside (mean)+6.9%
Target Range87.74 USD – 120.65 USD
87.74+6.9% to mean120.65
# Analysts4
Ownership
Shares Out.11.62M
Float3.65M
Insiders67.01%
Institutions10.80%
Technical
SMA 5087.34 (+8.4%)
SMA 20083.56 (+13.3%)
Beta0.77
S&P 52W Chg12.00%
Avg Vol (30d)6.71K
Avg Vol (10d)4.74K
Technical Indicators
RSI (14)57.3
MACD2.2195
MACD Signal2.6212
MACD Hist.-0.4016
BB Upper100.58 USD
BB Middle93.86 USD
BB Lower87.15 USD
BB Width14.31%
ATR (14)2.309 USD
Vol Ratio (20d)0.36x

About Vetoquinol (EPA: VETO)

›

Vetoquinol (EPA: VETO) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,526 employees.

The shares were at 86.30 EUR on 19 November 2026, up 19.4% over 52 weeks. Its 52-week range is 65.70 EUR to 91.50 EUR: the price is 5.7% below the high and 31.4% above the low.

At a market capitalisation of 1.00B EUR, it trades at 15.9 times trailing earnings and 14.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 36% for VETO. It pays a dividend yielding 1.08% (it pays out 17% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Vetoquinol reports return on equity of 9.7%, an operating margin of 16.0% and revenue up 0.6% year over year.

It holds more cash than debt, a net cash position of 222.85M EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 92.25 EUR is 6.9% above the current price. The next earnings report is expected on 25 March 2027.